NNovartis Read More Novartis’ Lp(a) drug misses key cardiovascular goal2026-09-21 Trial of 8,000+ people finds cardiovascular drug fails to cut heart attacks and strokes, leaving a key longevity…
NNovartis Read More Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)2026-09-04 Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the…
NNovartis Read More Unnatural Products inks $1.7b cardiovascular collab with Novartis2026-02-19 Company aims to drug the ‘undruggable’ with macrocyclic peptide approach that has potential in multiple age-related diseases. Curiously-named…